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Reflection & Reaction
Concomitant bilateral herpes zoster ophthalmicus
Hassan Pervez and colleagues1 present
a Clinical Picture purporting to show
concomitant bilateral herpes zoster
opthalmicus without providing
conclusive evidence of the diagnosis.
In the Tzanck test, the presence of
giant epithelial cells and multi-
nucleated giant cells in stained
material from the base of vesicular
lesions is taken to indicate the
presence of alpha herpes viruses, 
but does not identify the causative
agent. Antigen detection, nucleic 
acid testing, or viral culture of the
material is needed to establish
whether herpes simplex virus 1, 2, or
varicella zoster virus is responsible.
Laboratory diagnosis is of particular
relevance in this case given the
bilateral distribution of the rash 
(and the possible absence of
associated pain and eye involvement).
Identification of the specific virus
responsible is not an academic
exercise. Herpes simplex virus 
and varicella zoster virus warrant 
very different dosages of antiviral
medications and vary in their
prognostic significance, especially in
the elderly patient.
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Beauty and the beast
The recent violence in Nigeria around
the Miss World pageant highlights the
growing malaise and discontent of a
population that has suffered years of
poverty and neglect. Despite the
considerable wealth that has entered
Nigeria since the discovery of oil in
the southern regions, years of
corruption and mismanagement
mean that the general population has
yet to see any benefit. Nowhere is this
more poignant than within the
health-care sector,1 where Nigeria sees
some of the worst statistics in the
developing world despite a clear
capacity to respond. 
We spent several months last year
as part of a team that responded to a
large-scale measles epidemic in Kano
City, in the north of the country.
Epidemics of this nature persist in
Nigeria despite resources and the
availability of cheap affordable
vaccines, and this was one of the
worst measles epidemics in which
Médecins Sans Frontières (MSF) had
intervened. The outpatient
departments of two hospitals in which
we worked during the intervention
saw more than 13 000 measles cases,
from an estimated 70 000 cases in
Kano City alone. Despite medical
care, the case-fatality rate among
admissions was as high as 18%.
Epidemics of disease are highly
politicised in Nigeria and in Kano
State they are frequently covered up
by officials. For this reason, MSF was
not allowed to intervene with free
drugs and medical care until the
situation became desperate. Large-
scale epidemics with high case-fatality
rates occur with alarming regularity in
Nigeria. There are a number of
reasons for this. First, in the northern
regions the routine immunisation
system barely functions. Of nine
districts in Kano State, only one has a
functioning cold store—the others
lack functional refrigerators needed to
ensure the cold chain, have inter-
mittent electricity supplies, and
provide little or no training among
health-care professionals as to how to
protect vaccines from losing potency.2
There is no consistent vaccine supply
into the country; as a result, measles
vaccine-coverage rates are estimated
at between 15% and 25%, and efficacy
rates between 15% and 19%.2
Second, as is the case in much of
sub-Saharan Africa, the surveillance
systems in place to ensure timely
responses to epidemics are poor.
Substantial delay in the initiation of
emergency vaccination and social
mobilisation was certainly a
contributing factor to development of
complications and death among
children presenting to the hospital.
Finally, there are traditional and
religious issues, unique to this 
region, that affect treatment-seeking
behaviour. One study3 reported that
only 31% of mothers had taken their
children to formal health facilities
when they developed measles.
Instead, they administer local
concoctions to bring out the rash,
keep the child wrapped up, and do
not feed them. Malnutrition was a
prevailing factor among many of the
children, even in the absence of food
shortages within the region.
96 000 preventable measles-
related deaths are estimated to occur
every year in Nigeria.4 Although in
1990 UNICEF declared a victory in its
goal of immunising 80% of vulnerable
populations worldwide, this has for
many countries been unsustainable in
the face of war, internal conflict, the
HIV/AIDS pandemic, and waning
interest from international donors.
Nowhere is this more poignant than
within Nigeria, a country that clearly
has the wealth and capacity to
vaccinate its population with cheap
affordable vaccinations.
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